Stocks Performance to Track: Cerus Corporation (NASDAQ:CERS), Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)

0
45

Cerus Corporation (NASDAQ:CERS):

Last Trade:

Cerus Corporation (NASDAQ:CERS) ended its previous trading session at $5.07 with the Gain of 1.6%. The company’s market cap is $697.73 Million, and the average volume is $976.41 Million. The 52-Week High range of the stock is $8.05, while the 52-week low range is $3.38. The Price to Sales (P/S) of the stock is 9.38, while P/B (Price to Book) stands at 7.46. When we look at the Volatility of the company, Week Volatility is at 3.96% whereas Month Volatility is at 4.84%.


For the ongoing Fiscal Quarter, 2 analysts have an average earnings forecast of $-0.11 per share. According to the Analysts, the Low Earnings estimate for the current quarter is $-0.12, while the High earnings estimate is $-0.1.Comparatively, EPS for the same quarter last year was $-0.05.


According to 1 analysts, the Average Revenue Estimate for the current Fiscal quarter is $23.4 Million and the Low Revenue estimate is $23.4 Million, while the High Revenue estimate is $23.4 Million.


Cerus Corporation (NASDAQ:CERS) analysts on average have given a price target of $8.88 on CERS stock.


According to the Recommendation Trends of the stock polled by Zacks Investment Research for this month, the company has a consensus recommendation of 1.8 out of the scale from 1 to 5 where 1 stands for Strong Buy and 5 means Strong Sell.


Progenics Pharmaceuticals Inc. (NASDAQ:PGNX):


Previous Trade:

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) shares Jumped 3.7% and ended the day at $4.2. Its 52-week high and low range is between $9.42 and $3.62. The company’s outstanding shares are 86.62 Million. The volume of the company in the last trading session was 1.69 Million. The stock has a market cap of 363.8 Million. The Stock shows P/E value of 0 and Forward P/E of 0.


According to Finviz reported data, The SMA20 of the stock is at -5.03%, SMA50 is -14.73 percent, while SMA200 is -38.96%. The stock is currently has its Return on Assets (ROA) value of -36.4 Percent. The Return on Investment and Return on Equity (ROE) values are -44.6 percent and -73.7 percent, respectively.


The company’s ATR (Average True Range) is 0.31. The Weekly Volatility is 6.96% and the Monthly Volatility is 7.62%.


When we look at the Analyst Recommendations of the stock, the company has 1.6 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.


Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) analysts on average have given a price target of $8.88 on PGNX stock.


Progenics Pharmaceuticals Inc.’s Average Earnings Estimate for the current quarter is $-0.07, according to consensus of 1 analysts. The low EPS estimate is $-0.07, while the high EPS estimate is $-0.07.


Average Revenue Estimate of the company for the current Fiscal Quarter is $13.3 Million, according to consensus of 1 analysts. The higher end of the revenue estimate is $13.3 Million and the lower end is $13.3 Million.

SHARE

LEAVE A REPLY